Clinical Trials

200 enrolled 27 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07460752 2026-03-10

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

98 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT04423211 2026-03-02

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase 3 Recruiting

804 enrolled

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

10 enrolled

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT05827081 2026-03-02

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

310 enrolled

Prostatic Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

75 enrolled

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT04455750 2026-02-05

CASPAR

61 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

32 enrolled

Prostatic Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

60 enrolled

Hormone Sensitive Prostate Cancer

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

612 enrolled

Stage I Prostate Adenocarcinoma AJCC v7

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05122377 2026-01-06

RWE About QOL and Compliance of Patients With OFS in China

Completed

562 enrolled

Breast Neoplasms, Patient Compliance

NCT03942653 2025-12-31

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

20 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

87 enrolled

Breast Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

50 enrolled

Prostatic Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT03860987 2025-09-08

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

12 enrolled

Castrate Sensitive Prostate Cancer

NCT01492972 2025-09-04

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Phase 3 Recruiting

192 enrolled

Prostatic Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast Neoplasms

NCT04181203 2025-07-30

CARLHA-2

490 enrolled

Prostatic Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT02430480 2025-07-16

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

39 enrolled 21 charts

Prostatic Neoplasms

NCT06953882 2025-07-14

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

56 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00328614 2025-05-16

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Phase 1 Completed

32 enrolled 12 charts

Prostatic Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

19 enrolled 18 charts

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT00544830 2025-05-07

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

29 enrolled 12 charts

PSA Level Greater Than Two

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled